Memantine - Revision history

MDElliottMD: parser-claude: Memantine MedTemplate refill, Top 300 stub upgrade

2026-05-23T07:05:50Z

parser-claude: Memantine MedTemplate refill, Top 300 stub upgrade

← Older revision		Revision as of 07:05, 23 May 2026
Line 1:		Line 1:
	{{MedTemplate		{{MedTemplate
	\| generic = Memantine		\| generic = Memantine
	\| brand = Namenda		\| brand = Namenda (IR), Namenda XR (extended-release), Namzaric (with donepezil)
	\| structure =		\| structure =
	\| classes = Anti-dementia, ~~Dissociative~~		\| classes = [[:Category:Anti-dementia medicines\|Anti-dementia medicine]], [[:Category:NMDA receptor antagonists\|NMDA receptor antagonist (uncompetitive, low-affinity)]], [[:Category:Adamantanes\|Adamantane derivative]]
	\| ~~mechanism =~~ NMDA receptor antagonist		\| uses = <vote slug="alzheimer-moderate-severe-use">Alzheimer disease dementia, moderate to severe (FDA, often with donepezil)</vote>, <vote slug="vascular-dementia-memantine-use">Vascular dementia (off-label)</vote>, <vote slug="lewy-body-dementia-use">Lewy body dementia (off-label)</vote>, <vote slug="parkinson-disease-dementia-use">Parkinson disease dementia (off-label)</vote>
	\| uses =		\| starting_dose = 5 mg PO once daily; titrate by 5 mg weekly to target 10 mg PO BID. XR formulation: 7 mg/day, titrate to 28 mg/day
	\| starting_dose =		\| preparations = IR tablets 5, 10 mg; oral solution 2 mg/mL; XR capsules 7, 14, 21, 28 mg
	\| preparations =		\| fda_max = 20 mg/day (IR); 28 mg/day (XR)
	\| fda_max =		\| pill_id =
	\| routes =		\| routes = Oral
	\| onset =		\| onset = Cognitive effect emerges gradually over weeks to months; symptomatic effect only
	\| duration =		\| duration = BID dosing for IR; once-daily for XR
	\| halflife =		\| halflife = 60-100 hours (long)<ref name="namenda-label">FDA Prescribing Information, Namenda (memantine hydrochloride), Allergan/AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021487s019,021627s019lbl.pdf</ref>
	~~\| bioavailability =~~		\| bioavailability = ~100% (oral)<ref name="namenda-label" />
	~~\| pregnancy~~ =		\| pregnancy = Limited human data; rarely indicated in pregnancy given the patient population.{{citation needed}}
	~~\| legal~~ =		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| ~~intro =~~		\| mechanism = <vote slug="memantine-mech-claim">'''Uncompetitive, voltage-dependent NMDA receptor antagonist''' with low-to-moderate affinity. Binds within the open channel pore, preferentially blocking the pathological tonic NMDA activity that drives glutamate excitotoxicity in Alzheimer disease, while permitting the physiological transient NMDA activity required for long-term potentiation and memory formation. The "Goldilocks affinity" (strong enough to block excess but weak enough to detach during normal synaptic events) distinguishes memantine from high-affinity NMDA antagonists like ketamine, dextromethorphan, and phencyclidine that produce dissociative anesthesia.</vote> Symptomatic-only effect; does not alter the underlying neurodegenerative trajectory. Generally well tolerated; principal adverse effects are dizziness, headache, and confusion. Renally eliminated, with dose adjustment required in severe renal impairment<ref name="namenda-label" />.
	~~\| pharmacokinetics~~ =
	~~\| pharmacodynamics~~ =
	\| ~~indications~~ =
	\| ~~dosing~~ =
	\| ~~effects~~ =
	~~\| interactions~~ = <~~pharmaInteractions~~/>
	~~\| pregnancy_details =~~
	~~\| monitoring =~~
	~~\| counseling =~~
	~~\| anecdotes =~~
	~~\| seealso =~~
	~~\| references~~ =
	}}		}}

			== References ==
			<references />

	[[Category:Anti-~~Dementia Medicines~~]]		[[Category:Anti-dementia medicines]]
			[[Category:NMDA receptor antagonists]]
	[[Category:Adamantanes]]		[[Category:Adamantanes]]
	~~[[Category:NMDA receptor antagonists]]~~

CategoryClaude: Sentence-case category link per house style (NMDA_Receptor_Antagonists → NMDA_receptor_antagonists)

2026-05-23T05:02:22Z

Sentence-case category link per house style (NMDA_Receptor_Antagonists → NMDA_receptor_antagonists)

← Older revision		Revision as of 05:02, 23 May 2026
Line 34:		Line 34:
	[[Category:Anti-Dementia Medicines]]		[[Category:Anti-Dementia Medicines]]
	[[Category:Adamantanes]]		[[Category:Adamantanes]]
	[[Category:NMDA ~~Receptor Antagonists~~]]		[[Category:NMDA receptor antagonists]]

MDElliottMD: Tier 1 taxonomy consolidation: removed redundant Category:Anti-dementia (canonical already present)

2026-05-21T17:01:56Z

Tier 1 taxonomy consolidation: removed redundant Category:Anti-dementia (canonical already present)

← Older revision		Revision as of 17:01, 21 May 2026
Line 33:		Line 33:

	[[Category:Anti-Dementia Medicines]]		[[Category:Anti-Dementia Medicines]]
	~~[[Category:Anti-dementia]]~~
	[[Category:Adamantanes]]		[[Category:Adamantanes]]
	[[Category:NMDA Receptor Antagonists]]		[[Category:NMDA Receptor Antagonists]]

MDElliottMD: Comprehensive categorization: +Adamantanes, NMDA Receptor Antagonists

2026-05-15T18:42:17Z

Comprehensive categorization: +Adamantanes, NMDA Receptor Antagonists

← Older revision		Revision as of 18:42, 15 May 2026
Line 34:		Line 34:
	[[Category:Anti-Dementia Medicines]]		[[Category:Anti-Dementia Medicines]]
	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]
			[[Category:Adamantanes]]
			[[Category:NMDA Receptor Antagonists]]

MediaWiki default: Assign pharmacological categories from List_of_CNS-active_medicines

2026-05-14T15:07:06Z

Assign pharmacological categories from List_of_CNS-active_medicines

← Older revision		Revision as of 15:07, 14 May 2026
Line 31:		Line 31:
	}}		}}


			[[Category:Anti-Dementia Medicines]]
	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]

MDElliottMD: Pharmacopedia: add

2026-05-14T03:30:58Z

Pharmacopedia: add <pharmaInteractions/>

← Older revision		Revision as of 03:30, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	\| interactions =		\| interactions = <pharmaInteractions/>
	\| pregnancy_details =		\| pregnancy_details =
	\| monitoring =		\| monitoring =

MDElliottMD: Pharmacopedia: remove contraindications parameter

2026-05-14T02:40:40Z

Pharmacopedia: remove contraindications parameter

← Older revision		Revision as of 02:40, 14 May 2026
Line 22:		Line 22:
	\| dosing =		\| dosing =
	\| effects =		\| effects =
	~~\| contraindications =~~
	\| interactions =		\| interactions =
	\| pregnancy_details =		\| pregnancy_details =

MDElliottMD: Added empty fda_max parameter to MedTemplate call

2026-05-13T02:32:53Z

Added empty fda_max parameter to MedTemplate call

← Older revision		Revision as of 02:32, 13 May 2026
Line 8:		Line 8:
	\| starting_dose =		\| starting_dose =
	\| preparations =		\| preparations =
			\| fda_max =
	\| routes =		\| routes =
	\| onset =		\| onset =
Line 32:		Line 33:

	[[Category:Anti-dementia]]		[[Category:Anti-dementia]]

MDElliottMD: Expand stub to full MedTemplate parameter set

2026-05-13T01:00:00Z

Expand stub to full MedTemplate parameter set

@@ Line 1: / Line 1: @@
 {{MedTemplate
-| generic           = Memantine
+| generic            = Memantine
-| brand             = Namenda
+| brand              = Namenda
-| classes           = Anti-dementia, Dissociative
+| structure          =
-| mechanism         = NMDA receptor antagonist
+| classes            = Anti-dementia, Dissociative
 }}
 [[Category:Anti-dementia]]

MDElliottMD: Auto-created stub

2026-05-13T00:00:00Z

Auto-created stub

New page

{{MedTemplate
| generic = Memantine
| brand = Namenda
| classes = Anti-dementia, Dissociative
| mechanism = NMDA receptor antagonist
}}
[[Category:Anti-dementia]]